Targretin Articles
Eisai enters deals with Valeant and Minophagen
4 April 2012
Eisai licenses bexarotene to Minophagen forJapan; Roche opts for Invida for Korean marketing
4 April 2011
Stock Commentary - New York week to Sept 15, 2008
22 September 2008
Ligand to settle dispute with Salk Institute
15 September 2008
Stock Commentary - New York week to April 9
16 April 2007
Japan stock market week to Oct 30, 2006
6 November 2006
Ligand finalizes sale of oncology line to Eisai
6 November 2006
Japan stock market week to Sept 11, 2006
18 September 2006
Ligand sells oncology line to Eisai and Avinza to King for total $518M
18 September 2006
Ligand's 1st-qtr 2006 revenues up 38%
29 May 2006
Cephalon makes $360M cash offer for Zeneus
12 December 2005
Stock Commentary - New York
30 May 2005
Targretin: endpoints missed in NSCLC trials
4 April 2005
Ligand to request Nasdaq de-listing hearing
4 April 2005
Stock Commentary - New York
4 April 2005
Ligand sets up pain and oncology units
15 November 2004
Medeus acquires Elan business for $120M
23 February 2004
R&D costs offset 140% sales rise at Ligand
18 August 2003
Ligand's 2nd-qtr revenues up 10%, despite 15% loss growth
19 August 2002
Ligand launches Avinza in USA
15 July 2002
New data on Ligand's Targretin, Ontak
27 May 2002
Stock Commentary - New York
27 May 2002
Ligand revenues leap 59%, as product sales double
18 March 2002
CSFB starts coverage of Ligand
13 September 2001
Losses decline at Ligand, revenues up
1 May 2001
Ligand's Targretin capsules cleared in EU
5 April 2001
FDA approves Ligand's Targretin gel
6 July 2000
Ligand's Targretin gel nears full US approval
14 June 2000
Ligand's Targretin in psoriasis
4 May 2000
Ligand's Targretin, new data expected in 2000
29 March 2000
Ligand's Targretin gel gets priority review
10 February 2000
Ligand sells Marathon assets for $10 million
11 January 2000
Ligand completes marketing deal in Italy
7 January 2000
Cash boost for Ligand as Elan raises stake
4 January 2000
Ligand's Targretin effective in breast cancer?
16 December 1999
Ligand's Targretin wins partial backing
15 December 1999
Stock Commentary New York
2 December 1999
Stock Commentary New York
18 November 1999
Ligand's Targretin capsules get priority review
17 August 1999
Targretin capsules filed in USA
24 June 1999
Ligand's Targretin: Positive Animal Data
17 June 1999
Targretin effective in tamoxifen resistance
13 April 1999
Lilly scraps Targretin development agreement with Ligand
24 February 1999
FDA approves Ligand's Ontak for cutaneous T cell lymphoma
11 February 1999
Ligand Trials Targretin in Phase II Breast Cancer
9 December 1998
Ligand Announces Lilly, Seragen & Marathon Deals
12 May 1998
Scherer Working With Ligand On Softgel Products
9 March 1998
Ligand Planning Ph II Targretin Trials
12 February 1998
Ligand/Lilly Alliance Gets Underway
27 November 1997
Ist Qtr As Expected At Ligand
19 May 1997
Ligand Pharm Moves Ahead In 1996
7 April 1997
Ligand's Tagretin Sees 43% Response Rate In Cancer
26 March 1997
Numerous Clinical Trials Initiated In USA
9 September 1996
Ligand And ALRT; Retinoids Progress
15 January 1996
Ligand Retinoids Launch Double Assault On Kaposi's Sarcoma
16 October 1995
Showing 1-61 of 61 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
